ArticleChemMedChem2026
Redox Disruption Induced by Saquayamycin B1 Promotes Cytotoxicity in Resistant Melanoma Cells.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Melanoma is an aggressive skin cancer characterized by rapid progression and frequent chemoresistance, which limits the success of current therapies. Saquayamycin B1 (SQ-B1), an angucycline isolated from Streptomyces sp. I072, was investigated for its antimelanoma activity with emphasis on redox disruption. The compound was purified using M9 fermentation followed by semipreparative liquid chromatography, and its structure was confirmed through 1D/2D nuclear magnetic resonance (NMR) and mass spectrometry. Cytotoxicity assays (MTT, 72 h) in SK-MEL-5, -113, -117, and -134 cells revealed IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.